(Q36655451)

15 August 2017

1 reference

title

Pathogen-reduction systems for blood components: the current position and future trends (English)

1 reference

15 August 2017

Jerard Seghatchian

1

1 reference

15 August 2017

Gracinda de Sousa

series ordinal

2

1 reference

15 August 2017

publication date

15 November 2006

1 reference

Transfusion and Apheresis Science

15 August 2017

published in

1 reference

15 August 2017

volume

35

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

189-196

1 reference

Pathogen inactivation technology: cleansing the blood supply

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Current strategies on pathogen removal/inactivation: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Current strategies for the provision of safer plasma and its derivatives: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Current status of solvent/detergent-treated frozen plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Nanofiltration of plasma-derived biopharmaceutical products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Virus inactivation in blood components by photoactive phenothiazine dyes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

What's happening? The quality of methylene blue treated FFP and cryo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

A novel method for the assessment of pro- and anti-coagulant properties of platelet-derived microvesicles and its usefulness for quality monitoring of platelet haemostatic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Persistence of HTLV-I in blood components after leukocyte depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Positively charged porphyrins: a new series of photosensitizers for sterilization of RBCs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Binding affinities of commonly employed sensitizers of viral inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Immunologic reactivity in marrow graft recipients receiving cyclosporine to prevent graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

What is happening? Are the current acceptance criteria for therapeutic plasma adequate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.10.002

10.1016/J.TRANSCI.2006.10.002

7 January 2021

Identifiers

DOI

1 reference

release_7xtxvttuyrctbe2tyvkxbwdtsy

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7xtxvttuyrctbe2tyvkxbwdtsy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference